Skip to main content

Table 3 TEAEs that occurred in 5% or more of the subjects in the study

From: A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer’s dementia

System organ class Placebo, n = 410 GV-971 900 mg, n = 407
Number of events n (%) Number of events n (%)
Infectious and infectious diseases
 Urinary tract infection 45 40 (9.8%) 31 30 (7.4%)
 Nasopharyngitis 26 23 (5.6%) 34 30 (7.4%)
 Upper respiratory tract infection 36 30 (7.3%) 29 23 (5.7%)
Various types of inspection
 Elevated blood glucose 30 29 (7.1%) 32 28 (6.9%)
Various nervous system diseases
 Dizzy 28 24 (5.9%) 26 23 (5.7%)
Metabolic and nutritional diseases
 Hyperlipidemia 15 14 (3.4%) 29 29 (7.1%)